Selin Soyluoglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Selin Soyluoglu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ulku Korkmaz
Department of Nuclear Medicine, Faculty of Medicine, Trakya University, Edirne, Turkey
3 shared publications - Büşra Özdemir
Giresun Training and Research Hospital, Clinic of Nuclear Medicine, Giresun, Türkiye
2 shared publications - Gülay Durmuş Altun
Trakya Univ, Dept Nucl Med, Fac Med, Edirne, Turkey
2 shared publications Ahmet Polat
Sultan 1. Murat State Hospital, Clinic of Radiology, Edirne, Turkey
1 shared publicationAli Sarıkaya
Trakya University Faculty of Medicine, Department of Nuclear Medicine, Edirne, Turkey
1 shared publication- Berkin Ersoy1 shared publication
Latest Publications
- Open Access
- 29 September 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (39) , e35339
Assessment of three different radioiodine doses for ablation therapy of thyroid remnants: Efficiency, complications and patient comfort
I-131 radioiodine (RAI) ablation removes postoperative residual tissue and facilitates follow-up in low- and intermediate-risk differentiated thyroid cancer (DTC). Although low doses have been reported to be as effective as higher doses for ablation, the doses administered still vary depending on the patient and the practitioner. We aimed to evaluate the ablation efficiency, complications, and length of stay (LOS) of patients with DTC treated with 3 different doses for ablation. Patients with DTC who received RAI therapy were retrospectively reviewed. One hundred thirty patients with low-intermediate-risk, according to American Thyroid Association classification, without known lymph nodes or distant metastases were included. Patients were divided into 3 groups as 30 to 50 mCi, 75 mCi, and 100 mCi. Residue thyroid and salivary glands were evaluated from 9 to 12 months post-RAI I-131 scans. No significant difference was found between groups regarding ablation success (P = .795). In multivariable analyses, pretreatment thyroglobulin (hazard ratio = 0.8, 95% confidence interval 0.601–0.952, P = .017) and anti- thyroglobulin antibody (hazard ratio = 1.0, 95% confidence interval 0.967–0.998, P = .024) were 2 independent predictors of ablation success. The mean LOS was 2.1 ± 0.3, 2.6 ± 0.6, and 2.9 ± 0.4 days, respectively, (P = .001). LOS rates of ≥ 3 days were 13.2%, 54.3%, and 84.8%, respectively. Mild decreases in hemoglobin, white blood cell (WBC), and platelet counts were observed in all groups after 6 weeks without any clinically significant findings. A lower rate of change in WBC counts was observed in the 30 to 50 mCi group compared to others. There was no dose-dependent difference regarding the early complaints questioned. Ablation with 30 to 50 mCi provides benefits such as shorter LOS, better patient comfort, less salivary gland dysfunction, and less WBC suppression, thus reducing costs without decreasing efficacy.
- 29 September 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (39) , e35339
Open AccessAssessment of three different radioiodine doses for ablation therapy of thyroid remnants: Efficiency, complications and patient comfort
I-131 radioiodine (RAI) ablation removes postoperative residual tissue and facilitates follow-up in low- and intermediate-risk differentiated thyroid cancer (DTC). Although low doses have been reported to be as effective as higher doses for ablation, the doses administered still vary depending on the patient and the practitioner. We aimed to evaluate the ablation efficiency, complications, and length of stay (LOS) of patients with DTC treated with 3 different doses for ablation. Patients with DTC who received RAI therapy were retrospectively reviewed. One hundred thirty patients with low-intermediate-risk, according to American Thyroid Association classification, without known lymph nodes or distant metastases were included. Patients were divided into 3 groups as 30 to 50 mCi, 75 mCi, and 100 mCi. Residue thyroid and salivary glands were evaluated from 9 to 12 months post-RAI I-131 scans. No significant difference was found between groups regarding ablation success (P = .795). In multivariable analyses, pretreatment thyroglobulin (hazard ratio = 0.8, 95% confidence interval 0.601–0.952, P = .017) and anti- thyroglobulin antibody (hazard ratio = 1.0, 95% confidence interval 0.967–0.998, P = .024) were 2 independent predictors of ablation success. The mean LOS was 2.1 ± 0.3, 2.6 ± 0.6, and 2.9 ± 0.4 days, respectively, (P = .001). LOS rates of ≥ 3 days were 13.2%, 54.3%, and 84.8%, respectively. Mild decreases in hemoglobin, white blood cell (WBC), and platelet counts were observed in all groups after 6 weeks without any clinically significant findings. A lower rate of change in WBC counts was observed in the 30 to 50 mCi group compared to others. There was no dose-dependent difference regarding the early complaints questioned. Ablation with 30 to 50 mCi provides benefits such as shorter LOS, better patient comfort, less salivary gland dysfunction, and less WBC suppression, thus reducing costs without decreasing efficacy.
- 13 June 2023
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 57 (5) , 223-234
Contribution of Metabolic Parameters and Pericolic Fat Stranding on Preoperative 18F-FDG PET/CT in Predicting Post-operative Histopathology and Outcome in Colorectal Cancer
Purpose We aimed to investigate the additional value of preoperative PET/CT and reveal relationships between metabolic parameters, pericolic fat stranding finding, postoperative histopathology, and overall survival in colorectal cancer (CRC). Methods CRC patients who underwent preoperative PET/CT between January 2017-December 2021 were analyzed. Lymph nodes, organ metastases, and metabolic parameters were evaluated from PET/CT. The pericolic fat stranding was evaluated from CT component. Relationships between these factors and postoperative histopathological findings were statistically analyzed. Survival analyses were performed. Results Ninety-one patients (59 males, 32 females) were included in the study. All tumors showed high FDG uptake (mean SUVmax 19.5 ± 9.9). SUVmax of the tumor differed significantly at T3 and T4 stages (p = 0.041). A significant correlation was found between MTV, TLG values and the differentiation degree (p = 0.005, 0.003, respectively). PET/CT predicted the N stage with a high accuracy rate (80%). PET/CT found additional metastases that changed treatment decisions in one-third of patients. A relationship was found between tumor length, surgical margin, lymphovascular invasion and pericolic fat stranding. In multivariate analysis, differentiation degree (HR = 26.1, 95%CI 1.672–408.467), MTV (HR = 0.3, 95%CI 0.071–0.841), TLG (HR = 3.5, 95%CI 1.065–11.193), and lymphovascular invasion (HR = 0.2, 95%CI 0.026–0.853, p = 0.033) were independent factors affecting overall survival. Conclusion Preoperative PET/CT contributes to CRC management by detecting additional metastases as well as predicting prognosis and postoperative findings such as T stage, N stage and tumor differentiation. The SUVmax may differentiate between T3 and T4 tumor. Reporting of pericolic fat stranding may contribute to the estimation of lymphatic invasion and positive surgical margin.
- 13 June 2023
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 57 (5) , 223-234
Contribution of Metabolic Parameters and Pericolic Fat Stranding on Preoperative 18F-FDG PET/CT in Predicting Post-operative Histopathology and Outcome in Colorectal Cancer
Purpose We aimed to investigate the additional value of preoperative PET/CT and reveal relationships between metabolic parameters, pericolic fat stranding finding, postoperative histopathology, and overall survival in colorectal cancer (CRC). Methods CRC patients who underwent preoperative PET/CT between January 2017-December 2021 were analyzed. Lymph nodes, organ metastases, and metabolic parameters were evaluated from PET/CT. The pericolic fat stranding was evaluated from CT component. Relationships between these factors and postoperative histopathological findings were statistically analyzed. Survival analyses were performed. Results Ninety-one patients (59 males, 32 females) were included in the study. All tumors showed high FDG uptake (mean SUVmax 19.5 ± 9.9). SUVmax of the tumor differed significantly at T3 and T4 stages (p = 0.041). A significant correlation was found between MTV, TLG values and the differentiation degree (p = 0.005, 0.003, respectively). PET/CT predicted the N stage with a high accuracy rate (80%). PET/CT found additional metastases that changed treatment decisions in one-third of patients. A relationship was found between tumor length, surgical margin, lymphovascular invasion and pericolic fat stranding. In multivariate analysis, differentiation degree (HR = 26.1, 95%CI 1.672–408.467), MTV (HR = 0.3, 95%CI 0.071–0.841), TLG (HR = 3.5, 95%CI 1.065–11.193), and lymphovascular invasion (HR = 0.2, 95%CI 0.026–0.853, p = 0.033) were independent factors affecting overall survival. Conclusion Preoperative PET/CT contributes to CRC management by detecting additional metastases as well as predicting prognosis and postoperative findings such as T stage, N stage and tumor differentiation. The SUVmax may differentiate between T3 and T4 tumor. Reporting of pericolic fat stranding may contribute to the estimation of lymphatic invasion and positive surgical margin.
- Open Access
- 5 April 2023
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 57 (4) , 194-200
Radionuclide Therapy Videos on YouTube as An Educational Material: Has the COVID-19 Pandemic Changed the Quality, Usefulness, and Interaction Features
Introduction Current treatment approach aims to achieve greater efficacy with fewer side effects, by targeted cancer therapy as much as possible. Radionuclide therapy is a modality that uses cancer theranostics and is increasingly applied for various cancers as a targeted therapy. YouTube is a preferred tool for obtaining medical information from the internet. This study aims to determine the content quality, level of interaction and usefulness as education material of radionuclide therapy YouTube videos and to reveal the impact of the COVID-19 process on these parameters. Materials and Methods The keywords were searched on YouTube on August 25, 2018, and May 10, 2021. After removing duplicate and excluded videos, all remaining videos were scored and coded. Results Majority of the videos were useful educational material. Most of them were high quality. Popularity markers were unrelated to quality level. After COVID, the power index of videos with high JAMA scores increased. The COVID-19 pandemic did not have a negative effect on video features; the quality of the content increased even more after the pandemic. Conclusion Radionuclide therapy YouTube videos have high-quality content and provide useful education material. The popularity is independent of the content quality. During the pandemic, video quality and usefulness characteristics did not change, while the visibility is increased. We consider YouTube to be an appropriate educational material for patients and healthcare professionals to gain basic knowledge of radionuclide therapy. The Covıd-19 pandemic highlighted the power of radionuclide therapy YouTube videos as an educational material.
- 5 April 2023
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 57 (4) , 194-200
Open AccessRadionuclide Therapy Videos on YouTube as An Educational Material: Has the COVID-19 Pandemic Changed the Quality, Usefulness, and Interaction Features
Introduction Current treatment approach aims to achieve greater efficacy with fewer side effects, by targeted cancer therapy as much as possible. Radionuclide therapy is a modality that uses cancer theranostics and is increasingly applied for various cancers as a targeted therapy. YouTube is a preferred tool for obtaining medical information from the internet. This study aims to determine the content quality, level of interaction and usefulness as education material of radionuclide therapy YouTube videos and to reveal the impact of the COVID-19 process on these parameters. Materials and Methods The keywords were searched on YouTube on August 25, 2018, and May 10, 2021. After removing duplicate and excluded videos, all remaining videos were scored and coded. Results Majority of the videos were useful educational material. Most of them were high quality. Popularity markers were unrelated to quality level. After COVID, the power index of videos with high JAMA scores increased. The COVID-19 pandemic did not have a negative effect on video features; the quality of the content increased even more after the pandemic. Conclusion Radionuclide therapy YouTube videos have high-quality content and provide useful education material. The popularity is independent of the content quality. During the pandemic, video quality and usefulness characteristics did not change, while the visibility is increased. We consider YouTube to be an appropriate educational material for patients and healthcare professionals to gain basic knowledge of radionuclide therapy. The Covıd-19 pandemic highlighted the power of radionuclide therapy YouTube videos as an educational material.
- 30 June 2022
- Published by Galenos Yayinevi in TURKISH MEDICAL STUDENT JOURNAL
- Vol. 9 (2) , 55-58
EFFECTS OF THE COVID-19 PANDEMIC ON THE DEMOGRAPHIC OF ONCOLOGICAL PATIENTS AND THE USE OF PET/CT UTILIZATION
- 30 June 2022
- Published by Galenos Yayinevi in TURKISH MEDICAL STUDENT JOURNAL
- Vol. 9 (2) , 55-58
EFFECTS OF THE COVID-19 PANDEMIC ON THE DEMOGRAPHIC OF ONCOLOGICAL PATIENTS AND THE USE OF PET/CT UTILIZATION
- 17 May 2021
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 42 (10) , 1122-1129
68Ga-PSMA-I&T-PET/CT interobserver and intraobserver agreement for prostate cancer: a lesion based and subregional comparison study among observers with different levels of experience
Objective: 68Ga-PSMA-PET/CT is a relatively new technique, that is rapidly becoming widespread. We aimed to contribute interobserver–intraobserver agreement of 68Ga-PSMA-PET/CT, among low/high-experienced interpreters. Methods: 68Ga-PSMA-PET/CT of 56 patients with prostate cancer were evaluated blindly by four observers. Visual interpretation of malignant disease and SUVmax for lymph node (LN) regions, local tumor, bones and visceral organs were recorded. Cohen’s Kappa and Fleiss’ Kappa analyses were used to measure agreement between low/high/all-experienced observers. Variations were compared for regions, and the effect of prostate-specific antigen or Gleason score on the results was investigated. Results: Interobserver agreement was almost perfect for all LN regions (LN1 low-experienced κ: 0.84/0.84, high-experienced 0.89/0.96; LN2 low-experienced κ: 0.88/0.79, high-experienced 0.95/0.95; LN3 low-experienced κ: 0.84/0.89, high-experienced 0.87/0.94, first/second readings, respectively) and bone lesions (low-experienced κ: 0.88/0.88, high-experienced 0.92/0.92, first/second readings, respectively). For local tumor, interobserver agreement was substantially-almost perfect among a high-experienced group (κ: 0.74/0.89, first/second readings, respectively), and was moderate-substantial among a low-experienced group (κ: 0.62/0.56, first/second readings, respectively). Intraobserver agreement was almost perfect for three observers for all regions and substantial for the observer with the lowest experience in LN3, local and visceral lesions (κ: 0.74/0.79/0.62, respectively). Conclusion: Interpretation of prostate-specific membrane antigen (PSMA) for prostate cancer is acceptably consistent among observers, but some details are noteworthy. The evaluation should be done more algorithmically for local tumors, since all observers showed relatively lower agreement. The agreement increased as prostate-specific antigen and Gleason score increased. The observer with PSMA experience 68Ga-PSMA-PET/CT requires training with a small number of identified cases.
- 17 May 2021
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 42 (10) , 1122-1129
68Ga-PSMA-I&T-PET/CT interobserver and intraobserver agreement for prostate cancer: a lesion based and subregional comparison study among observers with different levels of experience
Objective: 68Ga-PSMA-PET/CT is a relatively new technique, that is rapidly becoming widespread. We aimed to contribute interobserver–intraobserver agreement of 68Ga-PSMA-PET/CT, among low/high-experienced interpreters. Methods: 68Ga-PSMA-PET/CT of 56 patients with prostate cancer were evaluated blindly by four observers. Visual interpretation of malignant disease and SUVmax for lymph node (LN) regions, local tumor, bones and visceral organs were recorded. Cohen’s Kappa and Fleiss’ Kappa analyses were used to measure agreement between low/high/all-experienced observers. Variations were compared for regions, and the effect of prostate-specific antigen or Gleason score on the results was investigated. Results: Interobserver agreement was almost perfect for all LN regions (LN1 low-experienced κ: 0.84/0.84, high-experienced 0.89/0.96; LN2 low-experienced κ: 0.88/0.79, high-experienced 0.95/0.95; LN3 low-experienced κ: 0.84/0.89, high-experienced 0.87/0.94, first/second readings, respectively) and bone lesions (low-experienced κ: 0.88/0.88, high-experienced 0.92/0.92, first/second readings, respectively). For local tumor, interobserver agreement was substantially-almost perfect among a high-experienced group (κ: 0.74/0.89, first/second readings, respectively), and was moderate-substantial among a low-experienced group (κ: 0.62/0.56, first/second readings, respectively). Intraobserver agreement was almost perfect for three observers for all regions and substantial for the observer with the lowest experience in LN3, local and visceral lesions (κ: 0.74/0.79/0.62, respectively). Conclusion: Interpretation of prostate-specific membrane antigen (PSMA) for prostate cancer is acceptably consistent among observers, but some details are noteworthy. The evaluation should be done more algorithmically for local tumors, since all observers showed relatively lower agreement. The agreement increased as prostate-specific antigen and Gleason score increased. The observer with PSMA experience 68Ga-PSMA-PET/CT requires training with a small number of identified cases.
- 31 March 2021
- Published by Bentham Science Publishers Ltd. in Current Radiopharmaceuticals
- Vol. 14 (1) , 15-22
Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Background: Theranostic is a new field of medicine that combines diagnosis and patient-specific targeted treatment. In the theranostic approach, it is aimed to detect diseased cells by using targeted molecules using disease-specific biological pathways and then destroy them by cellular irradiation without damaging other tissues. Diagnostic tests guide the use of specific therapeutic agents by demonstrating the presence of the receptor/molecule on the target tissue. Because the therapeutic agent is administered to patients who have a positive diagnostic test, the efficacy of treatment in these patients is largely guaranteed. As therapeutic efficacy can be predicted by therapeutic agents, it is also possible to monitor the response to treatment. Many diagnostic and therapeutic procedures in nuclear medicine are classified as theranostic. 131I treatment and scintigraphy is the best example of theranostic application. Likewise, 177Lu / 90Y octreotate for neuroendocrine tumors, 177Lu PSMA for metastatic or treatment-resistant prostate cancer, 90Y SIRT for metastatic liver cancer, and 223Ra for bone metastasis of prostate cancer are widely used. Also nanoparticles are one of the most rapidly developing subjects of theranostics. Diagnostic and therapeutic agents that show fluorescent, ultrasonic, magnetic, radioactive, contrast, pharmacological drug or antibody properties are loaded into the nanoparticle to provide theranostatic use. Method: This article will review general aspects of preclinical models for theranostic research, and present examples from the literature. Conclusion: To achieve successful results in rapidly accelerating personalized treatment research of today, the first step is to conduct appropriate preclinical studies.
- 31 March 2021
- Published by Bentham Science Publishers Ltd. in Current Radiopharmaceuticals
- Vol. 14 (1) , 15-22
Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Background: Theranostic is a new field of medicine that combines diagnosis and patient-specific targeted treatment. In the theranostic approach, it is aimed to detect diseased cells by using targeted molecules using disease-specific biological pathways and then destroy them by cellular irradiation without damaging other tissues. Diagnostic tests guide the use of specific therapeutic agents by demonstrating the presence of the receptor/molecule on the target tissue. Because the therapeutic agent is administered to patients who have a positive diagnostic test, the efficacy of treatment in these patients is largely guaranteed. As therapeutic efficacy can be predicted by therapeutic agents, it is also possible to monitor the response to treatment. Many diagnostic and therapeutic procedures in nuclear medicine are classified as theranostic. 131I treatment and scintigraphy is the best example of theranostic application. Likewise, 177Lu / 90Y octreotate for neuroendocrine tumors, 177Lu PSMA for metastatic or treatment-resistant prostate cancer, 90Y SIRT for metastatic liver cancer, and 223Ra for bone metastasis of prostate cancer are widely used. Also nanoparticles are one of the most rapidly developing subjects of theranostics. Diagnostic and therapeutic agents that show fluorescent, ultrasonic, magnetic, radioactive, contrast, pharmacological drug or antibody properties are loaded into the nanoparticle to provide theranostatic use. Method: This article will review general aspects of preclinical models for theranostic research, and present examples from the literature. Conclusion: To achieve successful results in rapidly accelerating personalized treatment research of today, the first step is to conduct appropriate preclinical studies.
- Open Access
- 1 February 2021
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 30 (1) , 8-17
The Diagnostic Contribution of SPECT/CT Imaging in the Assessment of Gastrointestinal Bleeding: Especially for Previously Operated Patients
Gastrointestinal bleeding (GIB) is a life-threatening problem that requires a multidisciplinary approach for successful treatment. This study aims to emphasize the clinical contribution of single photon emission computed tomography/computed tomography (SPECT/CT) for the diagnosis of acute bleeding. All 14 patients referred to the nuclear medicine department in 3 years with suspicion of acute GIB were evaluated retrospectively. Clinical records were analyzed to assess the scintigraphic findings, emphasizing the correlative contribution of the CT portion on SPECT/CT studies. Five patients were negative on dynamic and static planar images. SPECT/CT was performed in 9 patients who had positive findings on planar imaging. SPECT/CT could identify the same bleeding site originating from the anastomosis in four patients with a history of abdominal surgery. SPECT/CT confirmed bleeding from the cecum in a patient with cervical cancer. SPECT/CT showed the bleeding focus in the bladder neck of a patient with bladder cancer and the bleeding from peritoneal metastases of a patient with gastric cancer. In 1 patient, the right upper quadrant activity accumulation, which may cause false positives, was found to be the gallbladder on SPECT/CT. Delayed images showed the true bleeding focus in the cecum. In 1 patient, suspicious activity accumulation in the midline of the abdomen was found to be due to a previously unknown aortic aneurysm on SPECT/CT. SPECT/CT imaging is a feasible technique to facilitate image interpretation in patients with GIB. SPECT/CT imaging can guide the surgeon through more accurate localization. Therefore, for proper patient management, SPECT/CT should be applied to detect the bleeding focus, if present, especially in patients who had undergone a previous operation.
- 1 February 2021
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 30 (1) , 8-17
Open AccessThe Diagnostic Contribution of SPECT/CT Imaging in the Assessment of Gastrointestinal Bleeding: Especially for Previously Operated Patients
Gastrointestinal bleeding (GIB) is a life-threatening problem that requires a multidisciplinary approach for successful treatment. This study aims to emphasize the clinical contribution of single photon emission computed tomography/computed tomography (SPECT/CT) for the diagnosis of acute bleeding. All 14 patients referred to the nuclear medicine department in 3 years with suspicion of acute GIB were evaluated retrospectively. Clinical records were analyzed to assess the scintigraphic findings, emphasizing the correlative contribution of the CT portion on SPECT/CT studies. Five patients were negative on dynamic and static planar images. SPECT/CT was performed in 9 patients who had positive findings on planar imaging. SPECT/CT could identify the same bleeding site originating from the anastomosis in four patients with a history of abdominal surgery. SPECT/CT confirmed bleeding from the cecum in a patient with cervical cancer. SPECT/CT showed the bleeding focus in the bladder neck of a patient with bladder cancer and the bleeding from peritoneal metastases of a patient with gastric cancer. In 1 patient, the right upper quadrant activity accumulation, which may cause false positives, was found to be the gallbladder on SPECT/CT. Delayed images showed the true bleeding focus in the cecum. In 1 patient, suspicious activity accumulation in the midline of the abdomen was found to be due to a previously unknown aortic aneurysm on SPECT/CT. SPECT/CT imaging is a feasible technique to facilitate image interpretation in patients with GIB. SPECT/CT imaging can guide the surgeon through more accurate localization. Therefore, for proper patient management, SPECT/CT should be applied to detect the bleeding focus, if present, especially in patients who had undergone a previous operation.
- 16 November 2017
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 13 (4) , 422-430
A Lesion based and Sub-regional Comparison of FDG PET/CT and MDP Bone Scintigraphy in Detection of Bone Metastasis in Breast Cancer
Background: The aim of this study was to compare sensitivity, specificity and accuracy of 18F-FDG PET/CT and bone scintigraphy (BS) in detection of bone metastases in breast cancer patients; particularly according to anatomical regions, CT characteristics, tumor markers and hormone receptor status. Methods: Fifty patients, who received both FDG PET/CT and BS were retrospectively analyzed. Patients’ information including age, histological tumor type, hormone receptor positivity, c-erb B-2 oncogenes, tumor markers, clinical stages and subsequent clinical courses were reviewed. Lesion by lesion, regional and overall analyses was performed. The extent of metastases was assessed with twelve regions segmented bone scan index (BSI). The final diagnosis was established by histopathology, imaging and follow-up. Results: Overall sensitivity, specificity and accuracy were 83.2%, 100% and 87.6% for PET/CT, and 69.8%, 76.1% and 71.5% for BS. PET/CT was found to be more sensitive, specific and accurate for all regions, except cranium. While PET/CT was more sensitive in detecting osteolytic lesions, BS was more sensitive in detecting osteoblastic lesions. CA 15-3 levels were correlated with number of metastases for both techniques (P<0.05). Although PET/CT detected more metastatic lesions, the number of lesions detected with both techniques and the calculated BSI’s were not significantly different (p= 0.061, p= 0.053, respectively). BSI and number of totally detected metastases with both techniques were correlated with the final assessment. Conclusion: The sensitivity, specificity and accuracy of PET/CT in detecting overall and subregional bone lesions were significantly higher. Although PET/CT detected more metastatic lesions, both techniques seemed to supply complementary information to each other.
- 16 November 2017
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 13 (4) , 422-430
A Lesion based and Sub-regional Comparison of FDG PET/CT and MDP Bone Scintigraphy in Detection of Bone Metastasis in Breast Cancer
Background: The aim of this study was to compare sensitivity, specificity and accuracy of 18F-FDG PET/CT and bone scintigraphy (BS) in detection of bone metastases in breast cancer patients; particularly according to anatomical regions, CT characteristics, tumor markers and hormone receptor status. Methods: Fifty patients, who received both FDG PET/CT and BS were retrospectively analyzed. Patients’ information including age, histological tumor type, hormone receptor positivity, c-erb B-2 oncogenes, tumor markers, clinical stages and subsequent clinical courses were reviewed. Lesion by lesion, regional and overall analyses was performed. The extent of metastases was assessed with twelve regions segmented bone scan index (BSI). The final diagnosis was established by histopathology, imaging and follow-up. Results: Overall sensitivity, specificity and accuracy were 83.2%, 100% and 87.6% for PET/CT, and 69.8%, 76.1% and 71.5% for BS. PET/CT was found to be more sensitive, specific and accurate for all regions, except cranium. While PET/CT was more sensitive in detecting osteolytic lesions, BS was more sensitive in detecting osteoblastic lesions. CA 15-3 levels were correlated with number of metastases for both techniques (P<0.05). Although PET/CT detected more metastatic lesions, the number of lesions detected with both techniques and the calculated BSI’s were not significantly different (p= 0.061, p= 0.053, respectively). BSI and number of totally detected metastases with both techniques were correlated with the final assessment. Conclusion: The sensitivity, specificity and accuracy of PET/CT in detecting overall and subregional bone lesions were significantly higher. Although PET/CT detected more metastatic lesions, both techniques seemed to supply complementary information to each other.
- Open Access
- 27 February 2017
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 26 (1) , 43-46
Ectopic Pelvic Kidney Mimicking Sacral Metastasis on Post-Therapy Iodine-131 Scan of a Thyroid Cancer Patient
A 25-year-old woman had total thyroidectomy and iodine-131 ablation therapy for papillary thyroid carcinoma. Whole body imaging on the 7th day of therapeutic activity demonstrated radioiodine uptake in the remnant tissue and intense heterogeneous uptake at the sacral region prominently in the posterior image. Initial interpretation was suspicious for sacral metastasis. Technetium-99m-methylene diphosphonate bone scan demonstrated normal bone uptake and the absence of left kidney. On blood-pool phase of bone scan, the absence of left renal activity and an extra area of uptake in the sacral region suggestive of pelvic kidney were noticed. Magnetic resonance imaging scan confirmed the ectopic pelvic kidney overlying the sacrum.
- 27 February 2017
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 26 (1) , 43-46
Open AccessEctopic Pelvic Kidney Mimicking Sacral Metastasis on Post-Therapy Iodine-131 Scan of a Thyroid Cancer Patient
A 25-year-old woman had total thyroidectomy and iodine-131 ablation therapy for papillary thyroid carcinoma. Whole body imaging on the 7th day of therapeutic activity demonstrated radioiodine uptake in the remnant tissue and intense heterogeneous uptake at the sacral region prominently in the posterior image. Initial interpretation was suspicious for sacral metastasis. Technetium-99m-methylene diphosphonate bone scan demonstrated normal bone uptake and the absence of left kidney. On blood-pool phase of bone scan, the absence of left renal activity and an extra area of uptake in the sacral region suggestive of pelvic kidney were noticed. Magnetic resonance imaging scan confirmed the ectopic pelvic kidney overlying the sacrum.